Paper25058905
Cisplatin in cancer therapy: molecular mechanisms of action.
Dasari S and 1 other. Eur J Pharmacol, 2014. Cited by 3,949 papers, by iCite.
Cite this record
ConductScience Library. Cisplatin in cancer therapy: molecular mechanisms of action. Papers, record 25058905. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25058905
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Cisplatin | Major topic |
| Neoplasms | Major topic |
| Animals | |
| Drug Therapy, Combination | |
| Humans |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| G12 MD007581 | NIMHD NIH HHS | United States | G12MD007581 | PubMed and NIH |
| G12MD007581 | NIMHD NIH HHS | United States | G12MD007581 | PubMed and NIH |
Source NIH RePORTER
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT06263231 | A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) | Background |
Source ClinicalTrials.gov
References178
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12370430 | Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. | Proc Natl Acad Sci U S A | 2002 | https://conductscience.org/library/papers/12370430 | PubMed |
| 2 | 11085518 | Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. | Cancer Res | 2000 | https://conductscience.org/library/papers/11085518 | PubMed |
| 3 | 14576837 | Cisplatin: mode of cytotoxic action and molecular basis of resistance. | Oncogene | 2003 | https://conductscience.org/library/papers/14576837 | PubMed |
| 4 | 20935493 | Depletion of ribosomal protein L37 occurs in response to DNA damage and activates p53 through the L11/MDM2 pathway. | Cell Cycle | 2010 | https://conductscience.org/library/papers/20935493 | PubMed |
| 5 | 14751677 | Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. | Toxicology | 2004 | https://conductscience.org/library/papers/14751677 | PubMed |
| 6 | 23404433 | Combined anticancer activity of osthole and cisplatin in NCI-H460 lung cancer cells in vitro. | Exp Ther Med | 2013 | https://conductscience.org/library/papers/23404433 | PubMed |
| 7 | 12835670 | Ovarian cancer: strategies for overcoming resistance to chemotherapy. | Nat Rev Cancer | 2003 | https://conductscience.org/library/papers/12835670 | PubMed |
| 8 | 7939763 | Paclitaxel (Taxol) for the treatment of head and neck cancer. | Semin Oncol | 1994 | https://conductscience.org/library/papers/7939763 | PubMed |
| 9 | 23239809 | Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. | Mol Cancer Res | 2013 | https://conductscience.org/library/papers/23239809 | PubMed |
| 10 | 8375936 | Modulation of sensitivity of human ovarian cancer cells to cis-diamminedichloroplatinum(II) by 12-O-tetradecanoylphorbol-13-acetate and D,L-buthionine-S,R-sulphoximine. | Int J Cancer | 1993 | https://conductscience.org/library/papers/8375936 | PubMed |
| 11 | 23494564 | Synergistic interaction of β-galactosyl-pyrrolidinyl diazeniumdiolate with cisplatin against three tumor cells. | Arch Pharm Res | 2013 | https://conductscience.org/library/papers/23494564 | PubMed |
| 12 | 8515048 | A histochemical approach to the mechanism of action of cisplatin and its analogues. | J Histochem Cytochem | 1993 | https://conductscience.org/library/papers/8515048 | PubMed |
| 13 | 15986578 | The activities of liver adenosine deaminase, xanthine oxidase, catalase, superoxide dismutase enzymes and the levels of malondialdehyde and nitric oxide after cisplatin toxicity in rats: protective effect of caffeic acid phenethyl ester. | Toxicol Ind Health | 2005 | https://conductscience.org/library/papers/15986578 | PubMed |
| 14 | 2112183 | Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. | J Clin Oncol | 1990 | https://conductscience.org/library/papers/2112183 | PubMed |
| 15 | 8521815 | Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. | EMBO J | 1995 | https://conductscience.org/library/papers/8521815 | PubMed |
| 16 | 12495431 | Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. | Biochem J | 2003 | https://conductscience.org/library/papers/12495431 | PubMed |
| 17 | 1673965 | A phase II study of taxol in patients with malignant melanoma. | Invest New Drugs | 1991 | https://conductscience.org/library/papers/1673965 | PubMed |
| 18 | 20811617 | Cellular responses to Cisplatin-induced DNA damage. | J Nucleic Acids | 2010 | https://conductscience.org/library/papers/20811617 | PubMed |
| 19 | 19268559 | Caffeic acid phenethyl ester (CAPE) ameliorates cisplatin-induced hepatotoxicity in rabbit. | Exp Toxicol Pathol | 2010 | https://conductscience.org/library/papers/19268559 | PubMed |
| 20 | 16847145 | Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. | Mol Pharmacol | 2006 | https://conductscience.org/library/papers/16847145 | PubMed |
Cited by2,520
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3,949 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42985096 | Optimizing first-line therapy for advanced EGFR-mutated NSCLC: a patient-centered approach for low- and middle- income countries. | Front Oncol | 2026 | https://conductscience.org/library/papers/42985096 | PubMed |
| 42980935 | Gossypetin and luteolin, alone and with cisplatin, preferentially reduce MCF-7 breast cancer cell viability, whereas HeLa cervical cancer cells are refractory. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42980935 | PubMed |
| 42967962 | Crosstalk between chemotherapeutics and tumor-associated macrophages (TAMs): implications for tumor response. | J Cancer Res Clin Oncol | 2026 | https://conductscience.org/library/papers/42967962 | PubMed |
| 42955194 | Cubosome integrated with polymeric carbon nitride and cisplatin: in vivo biodistribution and in vitro photodynamic therapy studies. | Discov Nano | 2026 | https://conductscience.org/library/papers/42955194 | PubMed |
| 42949705 | Label-free Raman spectroscopy for cancer therapy response: from methodological framework to clinical translation. | Chem Soc Rev | 2026 | https://conductscience.org/library/papers/42949705 | PubMed |
| 42948278 | Cancer Evolvability Determines Therapy Outcomes. | Evol Appl | 2026 | https://conductscience.org/library/papers/42948278 | PubMed |
| 42943362 | Nelfinavir Synergizes with Cisplatin and Promotes GSDME-Associated Lytic Cell Death in Platinum-Resistant Ovarian Cancer Cells. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42943362 | PubMed |
| 42943233 | Biological Effects of Umbelliferone in MCF-7 Breast Cancer Cells: Integrated In Vitro and Computational Analyses. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42943233 | PubMed |
| 42940183 | A Non-Linear Ototoxic Response to Cisplatin Is Associated with Autophagy and PTEN/PI3K/AKT Signaling in Cochlear Hair Cells and Spiral Ganglion Neurons. | Biomedicines | 2026 | https://conductscience.org/library/papers/42940183 | PubMed |
| 42938830 | Beyond Platinum Resistance: Reconsidering Platinum Sensitivity as a Dynamic Phenotype in Ovarian Cancer. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42938830 | PubMed |
| 42932045 | Cannabidiol impairs tumor-associated behaviors and modulates apoptosis- and autophagy-related pathways in cisplatin-resistant head and neck squamous cell carcinoma. | Med Oncol | 2026 | https://conductscience.org/library/papers/42932045 | PubMed |
| 42927208 | SCML1 overexpression promotes DNA damage and improves the therapeutic efficacy of cisplatin for ovarian cancer. | iScience | 2026 | https://conductscience.org/library/papers/42927208 | PubMed |
| 42923595 | Potent Antineoplastic Activity against Breast Cancer in Vitro and in Vivo of a Chloro-Substituted Polyaromatic Platinum(II) Complex and Its Platinum(IV) Prodrug. | ACS Omega | 2026 | https://conductscience.org/library/papers/42923595 | PubMed |
| 42907850 | When drug repurposing backfires: antagonistic effects of ivermectin on cisplatin therapy in oral cancer. | BMC Pharmacol Toxicol | 2026 | https://conductscience.org/library/papers/42907850 | PubMed |
| 42895382 | Metal-dependent Structure, Solution Properties, and Redox-Mediated Anticancer Activity of Rhodium(III) and Iridium(III) Half-Sandwich Phenanthroline-Sulfonamide Complexes. | Inorg Chem | 2026 | https://conductscience.org/library/papers/42895382 | PubMed |
| 42883329 | Taking Charge Against the Silent Pandemic-Electrochemical Characterization of Drug Resistance. | Molecules | 2026 | https://conductscience.org/library/papers/42883329 | PubMed |
| 42877270 | Biodegradable ROS-Responsive TPCD Nanoparticles Mitigate Cisplatin-Induced Acute Kidney Injury via Synergistic Antioxidant and Immunomodulatory Actions. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42877270 | PubMed |
| 42867619 | The first formulation tailored for intraperitoneal delivery as a pressurised aerosol (PIPAC): doxorubicin-cisplatin as a fixed, ready-to-use drug combination. | Drug Deliv Transl Res | 2026 | https://conductscience.org/library/papers/42867619 | PubMed |
| 42866949 | Double-base deletions and signatures associated with platinum adducts in metastatic cancer. | Nucleic Acids Res | 2026 | https://conductscience.org/library/papers/42866949 | PubMed |
| 42831533 | Quercetin Attenuates Cisplatin-Induced Nephrotoxicity While Enhancing Antitumor Efficacy in Gastric Cancer via Cell Type-Specific Modulation of the ERK1/2 Pathway. | J Biochem Mol Toxicol | 2026 | https://conductscience.org/library/papers/42831533 | PubMed |
Genes77
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25058905
GET https://conductscience.org/api/papers/v1/25058905/references?page=2